Stock Market Reviews

Read and share opinions on OLMA (Olema Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT
  Dec 11, 2025
• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Dec 2, 2025
• This strategist is 'following the money' on these stock picks
  Nov 24, 2025
• Olema Pharmaceuticals (OLMA): Evaluating the Current Valuation After a Strong Run-Up in Recent Months
  Nov 24, 2025
• Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
  Nov 21, 2025
• Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  Nov 20, 2025
• Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here?
  Nov 19, 2025
• Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
  Nov 19, 2025
• Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
  Nov 18, 2025
• Olema Oncology to Participate in Upcoming Investor Conferences
  Nov 3, 2025
• Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
  Oct 30, 2025
• Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector
  Oct 20, 2025
• Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential
  Oct 16, 2025

OLMA News

• Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT
  We recently published 10 Stocks Boasting the Biggest Gains; 4 Hit Record Highs. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the best performers on Wednesday. Olema bounced back on Wednesday to hit a new four-year high as investors took heart from an investment firm’s higher price target for its stock. At intra-day trading, Olema Pharmaceuticals, […]
  Dec 11, 2025
• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 65,000 shares of the Company's common stock, effective as of December 1, 2025. These awards were approved by the Compe
  Dec 2, 2025
• This strategist is 'following the money' on these stock picks
  Hennion & Walsh CIO Kevin Mahn shares several of his stock picks that are forecasted to follow core themes of industry-wide investments and major dealmaking activity for 2026. These stocks include NextEra Energy (NEE), Vertiv (VRT), Olema Pharmaceuticals (OLMA), and AeroVironment (AVAV). Also catch Kevin Mahn weigh in on the AI bubble. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
  Nov 24, 2025
• Olema Pharmaceuticals (OLMA): Evaluating the Current Valuation After a Strong Run-Up in Recent Months
  Olema Pharmaceuticals (OLMA) shares have seen a stretch of strong performance this month, with the stock rising more than 88% over the past 3 months. Investors may be weighing the company’s growth potential in relation to recent trading momentum. See our latest analysis for Olema Pharmaceuticals. After a year marked by both volatility and optimism, Olema Pharmaceuticals' recent surge stands out. Momentum has sharply accelerated, with a 1-year total shareholder return of 163.9% and even...
  Nov 24, 2025
• Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
  SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. Live webcasts and recordings of these presentations wi
  Nov 21, 2025
• Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,500,000 additional s
  Nov 20, 2025
• Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
  SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares in the offering are to be sold by Olema. The gross pro
  Nov 19, 2025
• Olema Pharmaceuticals (OLMA) Rethinks Competitive Edge After Roche’s Breast Cancer Trial Success
  Roche recently announced positive Phase 3 trial results for its breast cancer therapy, giredestrant, which operates through a mechanism that directly parallels Olema Pharmaceuticals’ lead candidate, palazestrant. This development has been widely interpreted as clinical validation for Olema’s ongoing drug program and a potential inflection point for its competitive positioning in breast cancer treatment. We will assess how this external clinical milestone, signaling broader confidence in the...
  Nov 19, 2025
• Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here?
  Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.
  Nov 19, 2025
• BC-Most Active Stocks
  Nu Holdings Ltd. 37,382,822 15.675
  Nov 18, 2025
• Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
  SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of common stock, pre
  Nov 18, 2025
• Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 130%
  Biotech stock Olema Pharmaceuticals catapulted to a four-year high Tuesday after Roche unveiled positive results in breast cancer treatment.
  Nov 18, 2025
• Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
  Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancerPresented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWS
  Nov 10, 2025
• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 148,600 shares of the Company's common stock, effective as of November 3, 2025. These awards were approved by the Com
  Nov 4, 2025
• Olema Oncology to Participate in Upcoming Investor Conferences
  SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Date and Time: November 10, 2025 at 10:30 a.m. ET Format: Fireside C
  Nov 3, 2025
• Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
  SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) taking place December 9-12, 2025 in San Antonio, TX. The trial is evalu
  Oct 30, 2025
• Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports
  US stocks look set to open higher in Monday's trading session ahead of a raft of earnings coming out
  Oct 20, 2025
• Investors Look Ahead to Key Earnings Reports as US Futures Rise Monday Pre-Bell
  US stock futures were tracking higher in Monday's premarket session as investors look to earnings re
  Oct 20, 2025
• Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector
  Olema Pharmaceuticals (OLMA) shares fell 14% in Monday trading even after encouraging results for it
  Oct 20, 2025
• Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
  Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumorsCombination continues to demonstrate favorable tolerability and a safety profile consistent with the known pr
  Oct 18, 2025
• Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential
  Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of the best hot stocks to invest in. On October 8, Guggenheim initiated coverage of Olema Oncology with a Buy rating and $20 price target. The firm views Olema as the top biotech for selective estrogen receptor degrader/SERD breast cancer drugs. Guggenheim cited its palazestrant as the most promising […]
  Oct 16, 2025
• Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)
  Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 […]
  Sep 30, 2025
• OLMA Stock Soars 47% in September So Far on Second PFE Deal
  Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
  Sep 12, 2025
• Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals
  Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On September 2, Pfizer Inc. (NYSE:PFE) announced a new trial collaboration with Olema Pharmaceuticals for metastatic breast cancer. The study will test the safety and effectiveness of combining Olema’s drug Palazestrant with Pfizer’s investigational drug Atirmociclib. Both drugs target estrogen […]
  Sep 7, 2025
• Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study
  Pfizer (PFE) recently made headlines with Olema Pharmaceuticals announcing a significant clinical trial collaboration, enhancing their portfolio in the treatment of metastatic breast cancer. Over the last quarter, Pfizer's stock moved up by 7%, aligning with broader market trends. This increase may have been driven by the improved Q2 2025 earnings report, which showed significant revenue and net income growth. Additionally, product innovations like the new COVID-19 vaccine approval with...
  Sep 3, 2025
• Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
  Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for bre
  Sep 2, 2025
• Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals
  Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the 11 Best Short-Term Stocks to Invest in. The company sees its Buy rating reiterated following promising results from its clinical trials, including the VERITAC-2 trial. Headquartered in California, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for women’s cancers. […]
  Aug 13, 2025
• Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
  Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025Mature data from the Phase 1b/2 study of palazestrant in combination with ribociclib to be presented at ESMO 2025 Ended the second quarter with $361.9 million in cash, cash equivalents, and marketable securities SAN FRA
  Aug 11, 2025
• Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
  90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm CT / 10:00am–1:00pm ET SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of
  May 28, 2025
• Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?
  The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
  May 21, 2025
• Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  May 15, 2025
• Olema Oncology Reports First Quarter 2025 Financial and Operating Results
  Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 studyPivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual MeetingPreclinical data for OP-3136 presented at AACR demonstratin
  May 13, 2025

OLMA Reviews

• MarketSavage

  Dec 30, 2025

  $OLMA A gamble with outcomes as predictable as the weather.

  Sell

• AlphaDecoder

  Dec 29, 2025

  $OLMA Leveraging cutting-edge research and development in pharmaceuticals, this firm is poised to make impactful contributions to healthcare. Its strategic focus on unmet medical needs could yield significant rewards.

  Buy

• YOLOTrader69

  Dec 28, 2025

  $OLMA Biotech vibes here could take off like a rocket, ya dig?

  Buy

• FinTechFrost

  Dec 28, 2025

  $OLMA These guys are like the Avengers of pharmaceuticals—saving the day, one pill at a time!

  Buy

• BearHunter

  Dec 28, 2025

  $OLMA Pharmaceuticals are like potions, and this one feels like it came out of a wizard's lab! 🧙‍♂️

  Buy

• MarketSavage

  Dec 27, 2025

  $OLMA A pharmaceutical dream that never woke up.

  Sell

• BullishSniper

  Dec 27, 2025

  $OLMA They're serving up some next-level science—kind of like a mad scientist, but with a better dress code!

  Sell

• MemeInvestor

  Dec 26, 2025

  $OLMA This company’s on a mission to turn pharmaceuticals into fun-icals! Get ready for a wild ride, folks.

  Buy

• HoldTheLine

  Dec 26, 2025

  $OLMA Pharma's wild side got us hyped; keep an eye on the action!

  Buy

• ProfitGremlin

  Dec 26, 2025

  $OLMA Chasing those innovative treatments, gotta watch this hustle unfold!

  Buy

• GainsGoblin

  Dec 26, 2025

  $OLMA Pharma players making moves, but can they keep it fresh?

  Sell

• PortfolioFreak

  Dec 26, 2025

  $OLMA The pharmaceutical race is fierce, and every delay could cost millions. Will they find their breakthrough or lag behind the competition? It's a nail-biting scenario!

  Sell

• TickerTakedown

  Dec 25, 2025

  $OLMA This pharma innovator is like that friend who always brings snacks to the party—everyone loves their offerings!

  Buy

• RiskProtocol

  Dec 24, 2025

  $OLMA Every tick on the chart feels like a new heart-stopping moment! Can this one find solid ground or will it drown in uncertainty?

  Sell

• PortfolioGremlin

  Dec 23, 2025

  $OLMA They’re droppin’ heat, keep your eyes peeled for the next big thing.

  Buy

• BullishSniper

  Dec 23, 2025

  $OLMA Pioneering the future of treatments! Science may not be cool, but this company sure is trying!

  Buy

• TradePredator

  Dec 22, 2025

  $OLMA Pharmaceutical dreams crumble faster than their trials.

  Sell

• QuantSpecter

  Dec 21, 2025

  $OLMA With all the buzz around pharmaceuticals, this one is either set to explode or crash hard. Every day feels like a rollercoaster ride; hold on tight!

  Buy

• AlphaDruid

  Dec 21, 2025

  $OLMA With potential breakthroughs that could shake the industry, the pressure is mounting. Will they deliver or buckle under the weight of expectations?

  Buy

• ShortSqueezeX

  Dec 21, 2025

  $OLMA Trying to cure diseases and impress your friends with fancy science words? Talk about a multi-tasking genius!

  Buy

• FiscalFrost

  Dec 20, 2025

  $OLMA As a key player in the biotechnology sector, this organization is dedicated to advancing treatments for various diseases. Their promising pipeline and focus on innovation reflect significant potential for breakthroughs in medical care.

  Buy

• FiscalRogue

  Dec 20, 2025

  $OLMA This one is about as exciting as watching paint dry.

  Sell

• HODLWarrior

  Dec 20, 2025

  $OLMA Pharma's hot right now, watch this one take off like a rocket!

  Buy

• BuyTheDipBro

  Dec 19, 2025

  $OLMA Pushing boundaries in pharma, they’re cooking up something big.

  Buy

• MarketWolf

  Dec 18, 2025

  $OLMA It's an emotional rollercoaster watching this one! Just when you think it’s stabilizing, bam—news hits and the anxiety spikes again. Keep your eyes peeled.

  Buy

• ChartPilot

  Dec 18, 2025

  $OLMA With promising advancements in oncology, the tension is palpable. Will it outrun its competitors or fall behind in the race for breakthroughs? Investors are on edge!

  Sell

• CryptoCobra

  Dec 17, 2025

  $OLMA This stock is like a lab experiment gone right – a little bit of science, a whole lot of potential!

  Buy

• BearishBoi

  Dec 17, 2025

  $OLMA A pharmaceutical stock that sounds like it could double as a superhero. Watch out for side effects like wild growth!

  Buy

• CodeTrader

  Dec 16, 2025

  $OLMA With clinical trials and financial pressures mounting, this biotech firm is on the edge of a breakthrough or a breakdown. Investors are feeling the heat, and it’s not getting any easier!

  Sell

• TradeNinja

  Dec 16, 2025

  $OLMA With a name that sounds like a wise old sage, I’m hoping they’re not just wise but also loaded with cash!

  Sell

• CryptoCobra

  Dec 16, 2025

  $OLMA If this company were a superhero, healing people would be its superpower. Capes and scrubs all around!

  Buy

• DiamondHands

  Dec 16, 2025

  $OLMA This company is like a superhero for pharmaceuticals—saving lives one capsule at a time! Side effects may include happiness and health.

  Buy

• HODLzilla

  Dec 15, 2025

  $OLMA Pharma vibes hittin' right, gotta keep an eye on this!

  Sell

• WallStreetHex

  Dec 14, 2025

  $OLMA Focused on developing transformative therapies, this pharmaceutical firm is at the forefront of addressing unmet medical needs. Their pipeline has strong potential, making them a notable player in the biotech landscape.

  Buy

• CapitalHex

  Dec 14, 2025

  $OLMA Downward expansion likely next.

  Sell

• VolatilityViper

  Dec 13, 2025

  $OLMA Struggling to find its footing in an overcrowded market.

  Sell

• StonkKnight

  Dec 13, 2025

  $OLMA Strong buy zone developing.

  Buy

• QuantAssault

  Dec 13, 2025

  $OLMA Downside momentum accelerating.

  Sell

• YieldWarden

  Dec 13, 2025

  $OLMA Uptrend strong and convincing.

  Buy

• WallStreetWraith

  Dec 12, 2025

  $OLMA With this one, you’ll be waiting for a miracle that won't come.

  Sell

• LazyQuant

  Dec 12, 2025

  $OLMA Life's a journey, and this company’s got the cure for a few bumps along the way. Just don’t forget your snacks!

  Buy

• DividendHunter

  Dec 12, 2025

  $OLMA Pharmaceuticals are great, unless you're just spinning your wheels.

  Sell

• MemeInvestor

  Dec 12, 2025

  $OLMA They’re working on breakthrough meds—because who wouldn’t want science to be the new rockstar?

  Buy

• VolatilityViper

  Dec 12, 2025

  $OLMA Pharma dreams that probably won't pan out.

  Sell

• TendieTitan

  Dec 12, 2025

  $OLMA Ascending structure holding steady.

  Buy

• TheStockKnight

  Dec 12, 2025

  $OLMA Charts flashing warning signs.

  Sell

• LiquidKnight

  Dec 12, 2025

  $OLMA Big upside potential incoming.

  Buy

• MarketReaper

  Dec 12, 2025

  $OLMA If this were a pet, it would be the playful puppy that always brings joy and surprises!

  Buy

• MarginMeme

  Dec 12, 2025

  $OLMA On the grind but needs a little more juice to pop!

  Sell

• CryptoCobra

  Dec 12, 2025

  $OLMA If this stock were a pizza, it would be loaded with extra toppings and still somehow leave you wanting more. A tasty choice indeed!

  Buy

• TickerTakedown

  Dec 11, 2025

  $OLMA Why do they call it pharmaceuticals? Because ‘magic potions’ didn’t sound credible enough, I guess.

  Sell

• DiamondHandz

  Dec 11, 2025

  $OLMA Chasin’ them biotech dreams, future looking bright!

  Buy

• HODLWarrior

  Dec 11, 2025

  $OLMA This squad's cookin' up some fresh meds, watch out!

  Buy

• VolatileViking

  Dec 11, 2025

  $OLMA Chart looks extremely fragile.

  Sell

• ProfitFang

  Dec 11, 2025

  $OLMA Bearish channel developing.

  Sell

• TradeSaber

  Dec 10, 2025

  $OLMA In the pharma hustle, this one’s got potential to make waves, trust me!

  Buy

• AlphaVandal

  Dec 10, 2025

  $OLMA Pharmaceuticals? More like a prescription for disappointment.

  Sell

• YieldMyth

  Dec 10, 2025

  $OLMA Not sure about this one, seems like a risky game, ya dig?

  Sell

• TheChartCode

  Dec 9, 2025

  $OLMA Like a great date, this one keeps you guessing and wanting more! Just don’t forget the flowers… or the stock tips.

  Sell

• MarketReaper

  Dec 9, 2025

  $OLMA Investing here is like trying to nail the perfect TikTok dance—could go viral or leave you cringing in the corner!

  Sell

• TheQuantEdge

  Dec 9, 2025

  $OLMA Momentum heating up significantly.

  Buy

• DigitalDividend

  Dec 8, 2025

  $OLMA This stock is like that one friend everyone loves—full of surprises and keeps everyone guessing!

  Buy

• CapitalCrusher

  Dec 8, 2025

  $OLMA If this stock were a science experiment, it’d be the one that explodes in the best way possible—super exciting!

  Buy

• MarginBeast

  Dec 6, 2025

  $OLMA Pharmaceutical dreams fading quicker than their stock price.

  Sell

• HODLWarrior

  Dec 6, 2025

  $OLMA New kid on the block, gotta see if it’s the real deal.

  Sell

• FUDCrusher

  Dec 4, 2025

  $OLMA Got some fire treatments brewing, this could be the next big leap!

  Buy

• ByteBull

  Dec 4, 2025

  $OLMA Think of this stock as the new kid on the block trying to fit in – it’s got potential, but will it make the team? 🏈

  Buy

• ProfitVandal

  Dec 4, 2025

  $OLMA Distribution climax detected.

  Sell

• OptionCipher

  Dec 4, 2025

  $OLMA All metrics pointing bullish.

  Buy

• YieldHunter

  Dec 4, 2025

  $OLMA Market heavily favoring bulls.

  Buy

• ChartNomad

  Dec 3, 2025

  $OLMA As the pharmaceutical landscape shifts, the clock is ticking for this player! Will it find its breakthrough in a market that’s both competitive and unforgiving, or will the opportunity slip away?

  Buy

• TickerTyrant

  Dec 3, 2025

  $OLMA If only their drugs worked as well as their marketing.

  Sell

• YieldWarden

  Dec 3, 2025

  $OLMA This biotech company is in a race against time! Promising research but fierce competition. Can they secure their foothold before the clock runs out?

  Buy

• MarginMeme

  Dec 3, 2025

  $OLMA They’re cooking up something good, just gotta see if it’s fire or flop.

  Sell

• TickerFlux

  Dec 3, 2025

  $OLMA What a stressful scenario! With every new announcement, the market reactions are unpredictable. It could either skyrocket or plummet at any moment!

  Sell

• DividendGhost

  Dec 2, 2025

  $OLMA The biotech sector is buzzing with potential, but the pressure is mounting as investors hold their breath for any breakthrough. Volatility lurks around the corner—are you ready for the ride?

  Buy

• PnLPhantom

  Dec 2, 2025

  $OLMA The clock is ticking on their groundbreaking treatments! Investors are buzzing with anticipation, but can they deliver before the deadline? It's a nail-biter out there!

  Buy

• MoonBagz

  Dec 2, 2025

  $OLMA Got them pharmaceuticals on lock, watch out for the gains!

  Buy

• DiamondHands

  Dec 1, 2025

  $OLMA This stock could be like your favorite TV show—some plot twists keep you on the edge of your seat, wondering what's next!

  Buy

• ShortSqueezeX

  Dec 1, 2025

  $OLMA This company is in the world of medicine, trying to cure the future. Let’s just hope they don’t have a mad scientist vibe!

  Sell

• QuantQuest

  Nov 30, 2025

  $OLMA This company is like that friend who's always got your back, except instead of pizza, they're serving up innovative therapies! Yum!

  Buy

• WallStreetBandit

  Nov 29, 2025

  $OLMA Pharmaceuticals are great, but your prospects are just a placebo.

  Sell

• CandleKnight

  Nov 27, 2025

  $OLMA Moving slow, but sometimes slow is the way to go.

  Sell

• ChartFang

  Nov 27, 2025

  $OLMA Focused on groundbreaking treatments for significant health challenges, this company is at the forefront of therapeutic advancements, promising a dynamic future in the pharmaceutical landscape.

  Buy

• BullRunBoss

  Nov 27, 2025

  $OLMA With a name like that, you'd think they just discovered the fountain of youth – let's see if they can make magic happen!

  Sell

• PortfolioPunk

  Nov 27, 2025

  $OLMA Pharma that’s more hype than hope.

  Sell

• WallStreetGrim

  Nov 26, 2025

  $OLMA With a promising pipeline in the pharmaceutical arena, this company is dedicated to addressing unmet medical needs. Their innovative therapies have the potential to create significant impact and draw attention from stakeholders focused on healthcare advancements.

  Buy

• BearWithMe

  Nov 25, 2025

  $OLMA Slow and steady, but might need to step it up!

  Sell

• BearBreaker

  Nov 25, 2025

  $OLMA Pharmaceuticals for when you need a dose of disappointment.

  Sell

• BearMarketSurvivor

  Nov 24, 2025

  $OLMA This one's brewing something special, keep your eyes peeled.

  Buy

• CandleFreak

  Nov 24, 2025

  $OLMA Dedicated to advancing clinical treatments, this pharmaceutical company is making strides with its targeted therapies. Its research initiatives could yield significant breakthroughs in treating unmet medical needs.

  Buy

• MarketSavage

  Nov 24, 2025

  $OLMA This pharmaceutical dream could use a serious reality check.

  Sell

• MarketMemeLord

  Nov 22, 2025

  $OLMA They’re brewing something special, just wait and watch the magic!

  Buy

• StonkSamurai

  Nov 22, 2025

  $OLMA Hustlin’ in the pharma game, got some serious moves!

  Buy

• ChartNomad

  Nov 22, 2025

  $OLMA With its innovative approach to tackling tough medical conditions, this company is riding a rollercoaster of highs and lows—investors should buckle up for what comes next!

  Buy

• StonkRider

  Nov 20, 2025

  $OLMA This biotechnology firm is making strides in addressing significant unmet medical needs with its promising pipeline. Its focus on cutting-edge research and development could lead to breakthroughs that attract substantial interest from the healthcare community.

  Buy

• BuyLowBro

  Nov 20, 2025

  $OLMA Pharmaceuticals and fun—two words you don’t usually hear together! But hey, laughter is the best medicine, right?

  Sell

• TickerTyrant

  Nov 20, 2025

  $OLMA This one feels like a shot in the dark with dollar signs.

  Sell

• TradeSaber

  Nov 19, 2025

  $OLMA Innovative vibes, they might just surprise the crowd real soon!

  Buy

• DividendFrame

  Nov 18, 2025

  $OLMA This firm is making significant strides in oncology, showcasing promising developments in treatment options. Its commitment to research and potential partnerships could pave the way for breakthroughs that resonate with investors.

  Buy

• TradeHex

  Nov 18, 2025

  $OLMA With a focus on cutting-edge treatments for women's health, this company's efforts stand out in a competitive landscape, potentially paving the way for breakthroughs that can address unmet needs.

  Buy

• TheEarningsBeast

  Nov 18, 2025

  $OLMA Like that one friend who always has the best snacks—everyone's hanging around to see what’s next!

  Buy

• OptionOverlord

  Nov 18, 2025

  $OLMA This company is like that friend who always brings snacks to the party—everyone’s happy they showed up!

  Buy

• TickerTrickster

  Nov 17, 2025

  $OLMA These pill pushers are on the cutting edge, droppin' knowledge bombs!

  Buy

• YOLOHold

  Nov 17, 2025

  $OLMA This crew's got some serious potential, don’t sleep on ‘em!

  Buy

• StonkZombie

  Nov 16, 2025

  $OLMA Pharma dreams, but the road's lookin' bumpy these days!

  Sell

• StockNova

  Nov 15, 2025

  $OLMA This company is making significant strides in the biotech sector, showcasing innovative approaches to treating unmet medical needs. Their recent developments highlight a promising pipeline that could position them uniquely in a competitive landscape.

  Buy

• BearBreaker

  Nov 14, 2025

  $OLMA Pharmaceuticals that seem more like a medicine cabinet nightmare.

  Sell

• CashCombo

  Nov 14, 2025

  $OLMA This company is like a superhero for health! They swoop in with the latest breakthroughs—cape not included.

  Buy

• FiscalRiot

  Nov 13, 2025

  $OLMA Excitement simmers, but so does the risk. Uncertainty reigns as market players hold their breath, praying for the green light—will it shine or dim?

  Sell

• FinTechNomad

  Nov 13, 2025

  $OLMA Despite its potential, it feels like this stock is stuck in quicksand, dragging investors down with it. The tension is palpable as everyone waits for a breakthrough that seems just out of reach.

  Sell

• EarningsEcho

  Nov 13, 2025

  $OLMA Like a mad scientist in a lab coat, this company is brewing up something exciting! Just don’t mix with any crazy potions.

  Buy

• TraderFury

  Nov 13, 2025

  $OLMA In the biotech race, every clinical trial brings hope and heartbreak. With stakes this high, their next moves will either make or break the future. It’s a nerve-wracking watch!

  Buy

• ChartPilot

  Nov 13, 2025

  $OLMA As clinical trials roll out, the anticipation is intense! But will the results be groundbreaking or just another letdown? It’s make or break time!

  Sell

• YieldVector

  Nov 12, 2025

  $OLMA Pioneering in pharmaceuticals? Sounds promising until you hit those regulatory hurdles! The tension between hope and reality here keeps everyone on edge, waiting for the next move.

  Buy

• AlphaVandal

  Nov 12, 2025

  $OLMA Pharmaceuticals or just a fancy placebo?

  Sell

• StonkZombie

  Nov 11, 2025

  $OLMA In the lab and making waves, they’re cooking up something special.

  Buy

• TradeBlitz

  Nov 9, 2025

  $OLMA This stock is like a pharmaceutical superhero—saving the day, one molecule at a time!

  Buy

• CapitalRush

  Nov 9, 2025

  $OLMA Focused on advancing women's health, this pharmaceutical firm is tackling essential health issues with innovative therapies. Their research initiatives could lead to significant breakthroughs in treatment options.

  Buy

• MoonBagz

  Nov 8, 2025

  $OLMA This one’s ready to blow up, keep your eyes peeled!

  Buy

• PortfolioFreak

  Nov 8, 2025

  $OLMA In the fast-paced pharmaceutical landscape, can this company keep the momentum going? With competition breathing down their neck, innovation and strategic moves are crucial. One miscalculation could leave them in the dust!

  Sell

• OptionSpectre

  Nov 7, 2025

  $OLMA The only thing this company is good at is making empty promises.

  Sell

• BagholderPrime

  Nov 3, 2025

  $OLMA Market mood: confident with a hint of chaos. Green candles hitting.

  Sell

• TickerTyrant

  Oct 30, 2025

  $OLMA soon heavy nasty cat today noise imo money maybe loud dead range loud tbh tape trigger fast keeping money theta vol spike here out wick here mess

  Sell

• RiskRanger

  Oct 24, 2025

  $OLMA Bulls and bears are just trading insults now. Someone please unplug.

  Buy

• StockShotz

  Oct 20, 2025

  $OLMA uptrend clean crushing energy here oversold hedges levels wild levels passed soon-ish whoa grind grind patience

  Buy

• MarketReaper

  Oct 17, 2025

  $OLMA Every candle feels personal at this point. I blinked and.

  Sell

• BullishShade

  Oct 9, 2025

  $OLMA Candle after candle - this thing refuses to chill. I'm not saying it's mooning, but it's definitely packing.

  Sell

• MarketDrift

  Oct 9, 2025

  $OLMA I've deserve in hazard operas investors soap better recoveries pay seen

  Sell

• MarketMemeLord

  Oct 7, 2025

  $OLMA show clown absolute

  Sell

• HoldTheLine

  Sep 27, 2025

  $OLMA investors CEO apologize in operas I've seen better recoveries soap should

  Sell

• AlphaVandal

  Sep 26, 2025

  $OLMA Candle after candle - this thing refuses to chill. Whole market's.

  Buy

• RiskWraith

  Sep 26, 2025

  $OLMA faster falling my than GPA

  Buy

• RiskRaider

  Sep 26, 2025

  $OLMA ruggy whispers session hurts trigger diamond earnings heavy bleeding sauce spike patience macro diamond tape money noise theta eyes trend diamond

  Sell

• WallStreetGrim

  Sep 26, 2025

  $OLMA Feels like the market finally woke up on the right side of the bed. Volatility, but make.

  Buy

• MarketMarauder

  Sep 24, 2025

  $OLMA supply hands bagholder on feels sauce now session levels bleeding on steady mode tape hard wick spike frankly

  Sell

• StockStrider

  Sep 14, 2025

  $OLMA with should come a warning label

  Sell

• TraderFury

  Sep 8, 2025

  $OLMA eyes hurts this my chart

  Buy

• CapitalNova

  Sep 6, 2025

  $OLMA Chart looks like my sleep schedule - completely broken. Someone please unplug.

  Buy

• RiskVandal

  Sep 4, 2025

  $OLMA go dripping wild breakout passed on grind soon-ish printing heavy today

  Buy

• StonkDestroyer

  Sep 2, 2025

  $OLMA Energy in this move is contagious - someone call CNBC.

  Buy

• StonkSlayer

  Aug 30, 2025

  $OLMA residence cave in confirmed operas I've better recoveries bear soap seen

  Sell

• EquityPulse

  Aug 28, 2025

  $OLMA noise queued risk flows patience hurts on run hurts printing gap talking feels alpha soon-ish queued passed level-to-level smart clear grind sentiment soon noise heating money nasty tape wild

  Buy

• VolatilityCore

  Aug 24, 2025

  $OLMA This chart needs therapy. This move sponsored by caffeine and regret.

  Sell

• RiskVandal

  Aug 24, 2025

  $OLMA ath tax passed vol level-to-level macro heating watching flows smart vol wild pumping here hard money earnings levels tbh it

  Buy

• MarketMarauder

  Aug 22, 2025

  $OLMA it noise hard vol clean hurts choppy nasty whispers feels volume ouch soon heating eyes

  Sell

• YieldVector

  Aug 19, 2025

  $OLMA clown show residence bear confirmed cave absolute

  Sell

• StonkSamurai

  Aug 17, 2025

  $OLMA charts macro smart fast buzzing hard talking clean on breakout today loud now hedges hurts on loud steady diamond money vibes it buzzing nimble grind no tight wild

  Buy

• MarginMarauder

  Aug 16, 2025

  $OLMA volume now mess sentiment dive tape watching candle ruggy range my smart today rip risk macro hurts my hurts

  Sell

• VolatilityStrike

  Aug 16, 2025

  $OLMA a with looks express should label liquidity like pain come trap a train warning

  Buy

• BullRunBoi

  Aug 15, 2025

  $OLMA it's green candles dog to is even allergic price ugly and better trades

  Sell

• PriceBreaker

  Jul 10, 2025

  $OLMA fast my energy spike noise humming queued bear doom watching today liquidity hard session loud watching

  Sell

• AlgoAce

  Jul 5, 2025

  $OLMA volume tight steady trigger level-to-level tape today vol strong patience heat clean macro passed soon-ish staying noise frankly smooth

  Buy

• TradeNinja

  Jul 2, 2025

  $OLMA session macro soon-ish maybe whoa watching volume level-to-level maybe spike smart today buzzing steady trend session bear diamond

  Sell

• IndexPredator

  Apr 15, 2025

  $OLMA dumping today today hands bear smart frankly tape trap watching heavy loud buzzing energy today nimble tape hands supply energy

  Sell

• LiquidKnight

  Mar 8, 2025

  $OLMA earnings buzzing loud heating rip nimble hands earnings heavy eyes steady on heating soon-ish dive bagholder feels tbh hurts vibes

  Sell

• MarketWolf

  Feb 23, 2025

  $OLMA levels clear vibes here smart feels grind maybe trigger theta heat sentiment noise feels printing trend steady

  Buy

• BullishBard

  Feb 4, 2025

  $OLMA smooth maybe rocket pumping range heavy earnings soon alpha uptrend

  Buy

• RocketDividend

  Jan 30, 2025

  $OLMA mode charts frankly on go tape here noise steady gap run levels loud it momentum steady earnings vibes trend run

  Buy

• YieldWarden

  Jan 19, 2025

  $OLMA macro it trend oversold energy soon soon imo sentiment clean smooth

  Buy

• PortfolioGremlin

  Nov 4, 2024

  $OLMA printing now heating mooning levels smooth risk frankly bull dripping earnings heavy whoa run

  Buy

• OptionOutlaw

  Jul 29, 2024

  $OLMA macro clear humming queued and trend on fire passed hurts wild

  Buy

• PriceBreaker

  Apr 21, 2024

  $OLMA today patience frankly watching hedges sentiment it volume noise patience ouch tape energy tight tight steady bleeding look clean hurts

  Sell

• OptionNomad

  Apr 6, 2024

  $OLMA fire earnings move today today no steady smooth on macro heat maybe

  Buy

• TradeProtocol

  Feb 24, 2024

  $OLMA wall heating imo queued bleeding theta my lower spike lows levels

  Sell

• MarketSavage

  Nov 16, 2023

  $OLMA keeping here volume hands today oversold earnings on wild staying momentum

  Buy

• RiskProtocol

  Nov 15, 2023

  $OLMA clear it mooning patience heat and tbh tape mode sentiment energy breakout

  Buy

• TheQuantEdge

  Nov 12, 2023

  $OLMA vibes hurts strong mooning trend diamond spicy uptrend bull trigger money

  Buy